<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two pediatric patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, elevated antiplatelet antibody levels, refractoriness to human lymphocyte antigen-matched platelet transfusions, and sustained <z:mp ids='MP_0001914'>bleeding</z:mp> problems were treated with intravenous immunoglobulin (IVIG), pH 4.25, for three to over nine months </plain></SENT>
<SENT sid="1" pm="."><plain>Improved responses to platelet infusions and improved hemostasis were demonstrated in both patients </plain></SENT>
<SENT sid="2" pm="."><plain>A review of the published literature analyzing the role of IVIG in the treatment of platelet <z:e sem="disease" ids="C0948201" disease_type="Disease or Syndrome" abbrv="">alloimmunization</z:e> is presented </plain></SENT>
</text></document>